14-Chlorotetradec-1-ene | 71612-11-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 英文名称: 14-Chlorotetradec-1-ene
• 英文别名: 13-Tetradecenyl chloride
• CAS: 71612-11-8
• 化学式: C₁₄H₂₇Cl
• 分子量: 230.821
• InChiKey: ZIMFRFPTNXCPNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  15
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  15-Chloropentadecanoic acid 在 bis-triphenylphosphine-palladium(II) chloride 、 3,3’,5,5’-四叔丁基-2,2’-联苯二酚 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 neat (no solvent) 为溶剂， 反应 3.0h， 以75%的产率得到14-Chlorotetradec-1-ene
  参考文献：
  名称：

  钯催化脂肪酸脱羰脱水生产线性α烯烃

  摘要：

  报道了一种高效的钯催化羧酸脱羰脱水反应。该方法将丰富且可再生的偶数天然脂肪酸转化为有价值且昂贵的奇数α烯烃。此外，该化学品显示出高官能团耐受性。该工艺采用低负载量的钯催化剂，在无溶剂和相对温和的条件下进行。

  DOI：

  10.1002/adsc.201301109

文献信息

• [EN] USE OF SOLUBLE METAL SALTS IN METATHESIS REACTIONS<br/>[FR] UTILISATION DE SELS MÉTALLIQUES SOLUBLES DANS DES RÉACTIONS DE MÉTATHÈSE
  申请人：MATERIA INC

  公开号：WO2014152309A1

  公开（公告）日：2014-09-25

  The present invention describes the use of soluble metal salts to reduce impurities and metathesis catalysts poisons from olefinic feedstocks to improve olefin metathesis efficiency. The soluble metal salts were added to the olefinic feedstocks to prevent peroxides and catalyst poisons from inhibiting the metathesis catalyst. The soluble metal salts remain in the olefinic feedstocks and are used without further purification in the olefin metathesis reactions. The key to this invention is the soluble metal salt compounds do not inhibit the olefin metathesis catalysts but unexpectedly increase olefin metathesis catalyst efficiency while prior art heterogeneous metal complexes sequester the olefin metathesis catalyst, preventing olefin metathesis.

  本发明描述了利用可溶性金属盐来减少烯烃原料中的杂质和醚交换催化剂毒物，以提高烯烃醚交换效率。可溶性金属盐被添加到烯烃原料中，以防止过氧化物和催化剂毒物抑制醚交换催化剂。这些可溶性金属盐留在烯烃原料中，在烯烃醚交换反应中无需进一步纯化即可使用。这项发明的关键在于可溶性金属盐化合物不会抑制烯烃醚交换催化剂，而是意外地提高了烯烃醚交换催化剂的效率，而传统的异质金属络合物会固定烯烃醚交换催化剂，从而阻止烯烃醚交换。
• Cyclic Alkyl Amino Carbene (CAAC) Ruthenium Complexes as Improved Catalysts for Ethenolysis Reactions
  申请人：Marx Vanessa M.

  公开号：US20140309433A1

  公开（公告）日：2014-10-16

  Described herein are compounds and methods of catalyzing ethenolysis reactions, optionally on an industrial scale. In certain embodiments, the catalysts bear cyclic alkyl amino carbene (CAAC) ligands with an ortho substituent, such as a methyl substituent, on an N-aryl ring. When used to catalyze ethenolysis reactions, certain such compounds produce a turnover number greater than 50,000.

  本文描述了化合物和催化乙烯裂解反应的方法，可选择在工业规模上进行。在某些实施例中，催化剂带有带有一个N-芳基环上的一个类环烷基氨基甲烷（CAAC）配体的邻位取代基，例如一个甲基取代基。当用于催化乙烯裂解反应时，某些这样的化合物产生的周转次数大于50,000。
• PALLADIUM-CATALYZED DECARBONYLATION OF FATTY ACID ANHYDRIDES FOR THE PRODUCTION OF LINEAR ALPHA OLEFINS
  申请人：CALIFORNIA INSTITUTE OF TECHNOLOGY

  公开号：US20140155666A1

  公开（公告）日：2014-06-05

  The present invention is directed to methods of forming olefins, especially linear alpha olefins from fatty acids or anhydrides, each method comprising: contacting an amount of precursor carboxylic acid anhydride with a palladium catalyst comprising a bidentate bis-phosphine ligand in a reaction mixture so as to form an olefin in a product with the concomittant formation and removal of CO and water from the reaction mixture, either directly or indirectly, wherein the reaction mixture is maintained with a sub-stoichiometric excess of a sacrificial carboxylic acid anhydride, an organic acid, or both, said sub-stoichiometric excess being relative to the amount of the precursor carboxylic acid anhydride. The precursor carboxylic acid anhydride may be added to the reaction mixture directly or formed in situ by the reaction between at least one precursor carboxylic acid with a stoichiometric amount of the sacrificial acid anhydride.

  本发明涉及从脂肪酸或酸酐中形成烯烃的方法，特别是线性α-烯烃的方法，每种方法包括：将一定量的前体羧酸酐与含有双配位双膦配体的钯催化剂在反应混合物中接触，从而形成产物中的烯烃，并伴随着从反应混合物中直接或间接形成和去除CO和水，其中反应混合物保持有亚化学计量的献祭羧酸酐、有机酸或两者的过量，所述亚化学计量的过量相对于前体羧酸酐的量。前体羧酸酐可以直接加入反应混合物中，也可以由至少一种前体羧酸与化学计量的献祭酸酐之间的反应在原位形成。
• Oxime substituted therapeutic compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05770595A1

  公开（公告）日：1998-06-23

  Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula: CORE MOIETY--(R).sub.j including resolved enantiomers (both syn and anti forms) and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic and R may be selected from among: hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10), alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, and formula I. At least one R has the formula I: --(CH.sub.2).sub.n --C--(R.sub.1).sub.p, I wherein n is an integer from three to twenty; p is two or three; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; =N--OR.sub.2, R.sub.2 being hydrogen or a substitute or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; and --(CH.sub.2).sub.s --C(R.sub.3).sub.t (wherein s is zero or an integer from one to ten, t is two or three, R.sub.3 is hydrogen, halogen, hydroxide, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C(.sub.2-10) alkenyl, cyclic or heterocyclic group, or .dbd.N--OR.sub.2, R.sub.2 being defined above). At least one R.sub.1 or one R.sub.3 is .dbd.N--OR.sub.2, p or t corresponding to the at least one R.sub.1 or one R.sub.3 is two, and a second R.sub.1 or second R.sub.3, bonded to the same --C as the at least one R.sub.1 or one R.sub.3, is other than .dbd.N--OR.sub.2. These disclosed compounds are useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through specific intracellular signaling pathways.

  氧肟取代化合物最好是环状或杂环化合物。氧肟取代化合物及其药物组合物的化学式为：CORE MOIETY--(R).sub.j，包括已分离的对映体（同构体和反构体）和/或非对映异构体、水合物、盐、溶剂合物和它们的混合物。j为1到3的整数，核心基团是非环状或环状的，R可以从以下中选择：氢、卤素、羟基、氨基、取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、环状或杂环基团和式I。至少有一个R的式I为：--(CH.sub.2).sub.n --C--(R.sub.1).sub.p，其中n为3到20的整数，p为2或3，R.sub.1可以从以下中选择：氢、卤素、羟基、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基、环状或杂环基团；=N--OR.sub.2，其中R.sub.2为氢或取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、环状或杂环基团；以及--(CH.sub.2).sub.s --C(R.sub.3).sub.t（其中s为零或1到10的整数，t为2或3，R.sub.3为氢、卤素、羟基、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基、环状或杂环基团，或.dbd.N--OR.sub.2，其中R.sub.2如上所定义）。至少有一个R.sub.1或一个R.sub.3是.dbd.N--OR.sub.2，对应于至少一个R.sub.1或一个R.sub.3的p或t为2，与至少一个R.sub.1或一个R.sub.3结合的第二个R.sub.1或第二个R.sub.3不是.dbd.N--OR.sub.2。这些披露的化合物对于治疗或预防通过特定细胞内信号通路进行的介导疾病在许多治疗指标中是有用的。
• Epoxide-containing compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05866576A1

  公开（公告）日：1999-02-02

  Disclosed are enantiomers, diastereomers, salts, solvates, hydrates and mixtures thereof, of formula I: ##STR1## The core moiety is a monocyclic ring structure having five to six ring atoms and two nitrogen atoms at the 1 and 3 positions, n is an integer from 4 to 16, R.sub.1 and R.sub.2 are hydrogen, halogen or C.sub.1-12 alkyl or alkenyl, and (CH.sub.2).sub.n may be optionally substituted by a hydroxyl, halogen, oxygen, a C.sub.1-4 alkyl group or a dimethylamino group. The compounds and pharmaceutical composition thereof are useful in methods for treating an individual having a disease or treatment-induced toxicity mediated through a second messenger.

  本发明涉及公式I的对映体、二对映异构体、盐、溶剂物、水合物和其混合物，其中核心基团为具有五至六个环原子和1和3位置处的两个氮原子的单环环结构，n为4至16的整数，R.sub.1和R.sub.2为氢、卤素或C.sub.1-12烷基或烯基，而(CH.sub.2).sub.n可选择地被羟基、卤素、氧、C.sub.1-4烷基或二甲氨基基团取代。该化合物及其制药组合物在治疗通过第二信使介导的疾病或治疗引起的毒性的个体的方法中有用。